OJOph  Vol.4 No.1 , February 2014
Intravitreal Bevacizumab with Grid Photocoagulation for Recurrent Macular Edema Secondary to Retinal Vein Occlusion

Purpose: To assess the efficacy of intravitreal bevacizumab (IVB) combined with grid photocoagulation in the management of recurrent macular edema secondary to retinal vein occlusion (RVO). Methods: This is a prospective, non-randomized, interventional study. Thirty five eyes with branch retinal vein occlusion (BRVO) and 15 eyes with central retinal vein occlusion (CRVO) were treated with grid photocoagulation combined with IVB for recurrent macular edema. The visual acuity, central macular thickness and intraocular pressure were outcome measures. The mean duration of follow-up was 18.1 ± 3.6 months. Results: One month after treatment, 45 of the 50 eyes showed complete resolution of the cystoid space. Compared with initial values, final central macular thickness was reduced significantly in both BRVO and CRVO groups (P < 0.001), but improvement in VA was significant only for eyes with BRVO (P = 0.012). The total number of IVB was 1.8 ± 0.3 for eyes with either BRVO or CRVO. Conclusion: IVB combined with grid photocoagulation is an effective treatment for reducing recurrent macular edema associated with RVO.

Cite this paper
S. Mady and A. Ghanem, "Intravitreal Bevacizumab with Grid Photocoagulation for Recurrent Macular Edema Secondary to Retinal Vein Occlusion," Open Journal of Ophthalmology, Vol. 4 No. 1, 2014, pp. 6-11. doi: 10.4236/ojoph.2014.41002.

[1]   C. Pelzek and J. I. Lim, “Diabetic Macular Oedema: Review and Update,” Ophthalmology Clinics of North America, Vol. 15, No. 4, 2002, pp. 555-563.

[2]   J. M. Lahey, D. S. Fong and J. Kearney, “Intravitreal Tissue Plasminogen Activator for Acute Central Retinal Vein Occlusion,” Ophthalmic Surgery, Lasers and Imaging, Vol. 30, No. 6, 1999, pp. 427-434.

[3]   E. M. Opremcak, R. A. Bruce, M. D. Lomeo, et al., “Radial Optic Neurotomy for Central Retinal Vein Occlusion: A Retrospective Pilot Study of 11 Consecutive Cases,” Retina, Vol. 21, No. 5, 2001, pp. 408-415.

[4]   H. Noma, H. Funatsu, M. Yamasaki, et al., “Aqueous Humor Levels of Cytokines Are Correlated to Vitreous Levels and Severity of Macular Oedema in Branch Retinal Vein Occlusion,” Eye, Vol. 22, No. 1, 2008, pp. 42-48.

[5]   J. B. Jonas, I. Kreissig and R. F. Degenring, “Intravitreal Triamcinolone Acetonide as Treatment of Macular Edema in Central Retinal Vein Occlusion,” Graefe’s Archive for Clinical and Experimental Ophthalmology, Vol. 240, No. 9, 2002, pp. 782-783.

[6]   H. Noma, H. Funatsu, T. Mimura, et al., “Pigment Epithelialum-Derived Factor, Vascular Endothelial Growth Factor in Branch Retinal Vein Occlusion with Macular Edema,” Graefe’s Archive for Clinical and Experimental Ophthalmology, Vol. 248, No. 11, 2010, pp. 1559-1565.

[7]   D. B. Roth, C. Cukras, R. Radhakrishnan, et al., “Intravitreal Triamcinolone Acetnoide Injections in Treatment of Retinal Vein Occlusions,” Ophthalmic Surgery, Lasers and Imaging, Vol. 39, No. 6, 2008, pp. 446-454.

[8]   The Branch Vein Occlusion Study Group, “Argon Laser Photocoagulation for Macular Edema in Branch Vein Occlusion,” American Journal of Ophthalmology, Vol. 98, No. 3, 1984, pp. 271-282.

[9]   A. C. Kirchhoff, M. L. Drum, J. X. Zhang, et al., “Hypertension and Hyperlipidemia Management in Patients Treated at Community Health Centers,” Journal of Clinical Outcomes Management, Vol. 15, No. 3, 2008, pp. 125-131.

[10]   L. Wu, J. F. Arevalo, M. H. Berrocal, et al., “Comparison of Two Doses of Intravitreal Bevacizumab as Primary Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion: Results of the Pan American Collaborative Retina Study Group at 24 Months,” Retina, Vol. 30, No. 7, 2010, pp. 1002-1011.

[11]   D. M. Brown, P. A. Campochiaro, R. P. Singh, et al., “Ranibizumab for Macular Edema Following Central Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study,” Ophthalmology, Vol. 117, No. 6, 2010, pp. 1124-1133.

[12]   A. E. Hoeh, M. Ruppenstein, T. Ach and S. Dithmar, “OCT Patterns of Macular Edema and Response to Bevacizumab Therapy in Retinal Vein Occlusion,” Graefe’s Archive for Clinical and Experimental Ophthalmology, Vol. 248, No. 11, 2010, pp. 1567-1572.

[13]   P. A. Campochiaro, G. Hafiz, R. Channa, et al., “Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes,” Ophthalmology, Vol. 117, No. 12, 2010, pp. 2387-2394.e1-5.

[14]   H. Noma, H. Funatsu, T. Mimaura, et al., “Influence of Ischemia on Visual Function in Patients with Branch Retinal Vein Occlusion and Macular Edema,” Clinical Ophthalmology, Vol. 5, 2011, pp. 679-685.

[15]   M. Tyberg, V. Ponjavic and M. Lovestam-Adrian, “Multifocal Electroretinogram (mfERG) in Patients with Diabetes Mellitus and an Enlarged Foveal Avascular Azone (FAZ),” Documenta Ophthalmologica, Vol. 117, No. 3, 2008, pp. 185-189.

[16]   Y. Yamaguchi, T. Otani and S. Kishi, “Serous Macular Detachment in Branch Retinal Vein Occlusion,” Retina, Vol. 26, No. 9, 2006, pp. 1029-1033.

[17]   A Tsujikawa, A Sakamoto, M Ota, et al., “Serous Retinal Detachment Associated with Retinal Vein Occlusion,” American Journal of Ophthalmology, Vol. 149, No. 2, 2010, pp. 291.e5-301.e5.

[18]   D. Finkelstein, “Ischemic Macular Edema. Recognition and Favorable Natural History in Branch Vein Occlusion,” Archives of Ophthalmology, Vol. 110, No. 10, 1992, pp. 1427-1434. http://dx.doi.org/10.1001/archopht.1992.01080220089028